CLASS II ONGOING Device recall · Reported 24 Sep 2025 · FDA Enforcement Report

FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26 recalled

Agilent Technologies Denmark ApS is recalling FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) is intended, distributed nationwide in the US. The recall was initiated on 11 Aug 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot numbers: 41781549, 41762487, 41651581 GTIN:
Quantity recalled65

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2564-2025
FDA event ID
97421
Recalling firm
Agilent Technologies Denmark ApS, Glostrup, N/A
Classification
Class II
Status
Ongoing
Recall initiated
11 Aug 2025
FDA classified
15 Sep 2025
Reported
24 Sep 2025
Type
Voluntary: Firm initiated
Customers notified by
N/A
Reason category
Device Malfunction
Device type
Medical Software

Timeline

11 Aug 2025Recall initiated by company
15 Sep 2025Classified by FDA+35 days
24 Sep 2025Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Their is the potential for weak staining which may result in false negative CD20 identification.

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

Brand Name: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) Model/Catalog Number: GA60461-2CN Software Version: Not applicable Product Description: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) is intended for use in immunohistochemistry together with the Dako Omnis instrument. This antibody labels cells of the B-cell lineage and is a useful aid for the classification of neoplasms of B-cell derivation. Component: Not applicable

Where it was distributed

US Nationwide distribution including in the states of Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Nevada, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin.

Nationwide AlabamaCaliforniaColoradoConnecticutFloridaGeorgiaIllinoisIndianaKentuckyLouisianaMassachusettsMarylandMaineMichiganMississippiNorth CarolinaNorth DakotaNew JerseyNevadaNew York

Questions about this recall

Is FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) is intended recalled?

Yes. Agilent Technologies Denmark ApS recalled FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) is intended on 11 Aug 2025. The recall is Class II and its status is Ongoing. Recall number Z-2564-2025.

Why was it recalled?

Their is the potential for weak staining which may result in false negative CD20 identification.

Which lots are affected?

Lot numbers: 41781549, 41762487, 41651581 GTIN:

Where was it sold?

US Nationwide distribution including in the states of Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Nevada, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Agilent Technologies Denmark ApS

All 3

Other Medical Software recalls

All 903